Navigation Links
Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Date:8/20/2007

Company Announces Clinical Trial Plans for 4Q07/1Q08

DALLAS, Aug. 20 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) provided today an update on the clinical development plan of ProLindac, its novel DACH platinum polymer prodrug, and announced plans for additional human clinical trials to be initiated in late 2007/ early 2008. The ongoing clinical trial in recurrent ovarian cancer patients, designed to optimize single agent dosing through schedule diversification and dose escalation, is currently successfully completing the enrollment of its third dose cohort.

"The excellent safety profile, especially the lack of neuro- and nephrotoxicity after multiple treatment cycles, makes it possible for us now to submit an amendment to the ongoing trial which will allow us to further and aggressively explore dosing and schedule optimization in a quicker manner," stated Dr. Esteban Cvitkovic, Vice Chairman (Europe) and recently appointed Senior Director Clinical Oncology. "The recurrent ovarian patient population is an increasingly challenging indication from a regulatory standpoint. Therefore we will continue to be careful with patient eligibility in this single agent trial. We have observed a pharmacological effect at what are still sub-toxic doses which leaves room to increase the therapeutic index in this specific indication. Moreover, this will also allow us to implement combination drug trials, the other main path to obtain further clinical evidence, in a variety of indications, of the full potential for this very promising agent."

Access Pharmaceuticals is currently planning ProLindac drug combination trials to be initiated in the fourth quarter of 2007/early 2008. As has been clinically demonstrated with Eloxatin, Sanofi's marketed DACH platinum, ProLindac's antitumor effect is expected to be synergistic when utilized in combination with other reference anti-cancer agents, such as 5-fluorourcil (5FU) or
'/>"/>

SOURCE Access Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
3. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015  Seeger Weiss LLP is reporting that on July ... letter to C.R. Bard, the manufacturer of Inferior vena ... correct violations the agency found at two of Bard,s facilities. ... FDA cited them during Inspectional Observations that occurred on November ... Tempe, AZ , location and on October 6, 2014, ...
(Date:7/31/2015)... , July 31, 2015 ... Review, 2015 market research report that provides an ... stage using data sourced from in-house databases, secondary ... syringes and needles market products pipeline spread across ... supported with 73 tables and 5 figures is ...
(Date:7/31/2015)... According to a new market research ... Heat, Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), ... Global Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment ... 2020, at a CAGR of 7.6%.from 2015 to 2020. ... T ables and 37 F ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4
... Pa., Feb. 16, 2011 AirPal, a medical device ... of allowance from the U.S. Patent Office for its ... for situations such as difficult airway management, laryngoscopies, diagnostic ... founded in 1982, now holds more than a dozen ...
... YORK, Feb. 16, 2011 Get content from ... The European Parliament is expected ... prevent falsified medicines from entering the legal distribution ... packages have reached patients in the last years. ...
Cached Medicine Technology:AirPal Receives Patent for Inflatable Patient Positioning Systems 2
(Date:7/31/2015)... ... , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and ... of Exilis non-surgical fat reduction in New York. Due to its unparalleled level ... clientele. Many patients travel to New York to get their non-surgical skin tightening ...
(Date:7/31/2015)... ... 31, 2015 , ... The 2nd annual Ride to Fight On will start ... 3, 2015. The Ride to Fight On is a cycling fundraiser that benefits the ... West Clinic and The University of Tennessee Health Science Center. A health and wellness ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and ... True North Conference Center. The medical community, social workers, law enforcement, and government ... more aligned in the effort to better understand and combat sex trafficking. Lead ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc ... Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an ... preparing for the exam easy and painless. MDLinx offers thousands of board-exam style ...
(Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... SOUTH WINDSOR, Conn., Oct. 1 UTC Power, ... today announced it has,acquired Dome- Tech Group, a ... and New York City. Financial terms were not ... reduce energy costs,and improve overall efficiency. It facilitates ...
... genetics may be to blame, researchers suggest, , , MONDAY, ... is generally considered a good thing, new research suggests ... harm the health of the fetus. , Expectant ... per deciliter (mg/dL) gave birth -- on average -- ...
... Measures to Recognize Value and Enhance Payments, ... private insurers threaten the future of many of ... ability to continue serving all,patients, concludes a new ... New York State (CHCANYS), and funded by CHCANYS ...
... 2007 Two studies in the October issue of ... the use of colonoscopy to screen for colorectal cancer. ... or adenomaspre-cancerous growths that may develop into colorectal cancerson ... with only a few small polyps can be screened ...
... Newer ultrasound and magnetic resonance (MR) imaging tests ... and cirrhosis of the liver, according to three ... Clinical Gastroenterology and Hepatology. , With further research, ... the need for biopsiesprocedures done to obtain a ...
... of the first large-scale studies to examine the association of ... dwelling of older women finds that poorer sleep is associated ... according to a study published in the October 1 issue ... E. Goldman, PhD, of the University of Pittsburgh, was based ...
Cached Medicine News:Health News:UTC Power Acquires Dome-Tech Group 2Health News:Mom's Low Cholesterol Tied to Preemie Births 2Health News:Mom's Low Cholesterol Tied to Preemie Births 3Health News:Commercial Insurers' Reimbursement Rate to New York's Community Health Centers Jeopardizes Care 2Health News:Commercial Insurers' Reimbursement Rate to New York's Community Health Centers Jeopardizes Care 3Health News:Commercial Insurers' Reimbursement Rate to New York's Community Health Centers Jeopardizes Care 4Health News:Studies lend insights into colorectal cancer screening 2Health News:Studies lend insights into colorectal cancer screening 3Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 2Health News:Noninvasive tests for cirrhosis may help to avoid liver biopsy 3Health News:Journal SLEEP: disturbed sleep linked to poorer daytime function in older women 2Health News:Journal SLEEP: disturbed sleep linked to poorer daytime function in older women 3
... Intended for the quantitative determination ... serum or plasma. Liquid buffer ... Phosphate tablets must be purchased ... method. Kinetic reaction. Wavelength: 340 ...
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Intended for the quantitative determination of total protein in serum. Reaction: endpoint. Wavelength: 540 nm. Linearity: 12 g/dL (120 g/L). Ready to use liquid reagent....
Urea nitrogen (BUN) liquid reagent is used for the kinetic quantitative determination of Urea Nitrogen (BUN) in human serum used in routine examination and monitoring of therapy and relapses....
Medicine Products: